DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age40+
SponsorOhio State University Comprehensive Cancer Center
About this trial
Up to 80% of breast cancer survivors experience chemotherapy-induced neuropathy that impairs quality of life and increases fall risk long into survivorship, yet treatment options for neuropathy remain limited. The successful treatment will target neurophysiologic mechanisms for restoring function while addressing patient-reported symptoms and participation in treatment. Toward this end, the investigators propose to study a noninvasive, social sensorimotor intervention - Adapted Argentine Tango - which targets motor control restoration, symptom alleviation, and treatment participation in concert.
Eligibility criteria
Qualifiers
Breast Cancer (BC) diagnosis of Stage I-IV including metastatic disease
completed taxane-based chemotherapy for BC at least 3 months ago (no limit on how long ago)
symptomatic for chemotherapy-induced neuropathy (self-report)
postural control score that indicates potential fall-risk
Disqualifiers
pre-existing vestibular dysfunction
poorly controlled diabetes (hgA1C>=8)
non-ambulatory (assistive and prosthetic devices allowed)
hearing impairment resulting in less than 10% hearing bilaterally
Trial design
Treatments tested in this trial
- Tango
Treatment groups
140 Participants
are divided into 2 treatment groupsSponsors and collaborators
Ohio State University Comprehensive Cancer Center
Lead sponsor
National Institute on Aging (NIA)
Collaborator
Yale University
Collaborator
Emory University
Collaborator
Source ClinicalTrials.gov